266 related articles for article (PubMed ID: 18255187)
1. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
Hotte SJ; Hirte HW; Chen EX; Siu LL; Le LH; Corey A; Iacobucci A; MacLean M; Lo L; Fox NL; Oza AM
Clin Cancer Res; 2008 Jun; 14(11):3450-5. PubMed ID: 18519776
[TBL] [Abstract][Full Text] [Related]
3. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
Tolcher AW; Mita M; Meropol NJ; von Mehren M; Patnaik A; Padavic K; Hill M; Mays T; McCoy T; Fox NL; Halpern W; Corey A; Cohen RB
J Clin Oncol; 2007 Apr; 25(11):1390-5. PubMed ID: 17416859
[TBL] [Abstract][Full Text] [Related]
4. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
von Pawel J; Harvey JH; Spigel DR; Dediu M; Reck M; Cebotaru CL; Humphreys RC; Gribbin MJ; Fox NL; Camidge DR
Clin Lung Cancer; 2014 May; 15(3):188-196.e2. PubMed ID: 24560012
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer.
Vokes EE; Figlin R; Hochster H; Lotze M; Rybak ME
Cancer J Sci Am; 1998; 4(1):46-51. PubMed ID: 9467046
[TBL] [Abstract][Full Text] [Related]
9. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G
J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.
Riely GJ; Gadgeel S; Rothman I; Saidman B; Sabbath K; Feit K; Kris MG; Rizvi NA
Lung Cancer; 2007 Feb; 55(2):181-5. PubMed ID: 17092603
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.
Trarbach T; Moehler M; Heinemann V; Köhne CH; Przyborek M; Schulz C; Sneller V; Gallant G; Kanzler S
Br J Cancer; 2010 Feb; 102(3):506-12. PubMed ID: 20068564
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.
Ohe Y; Ichinose Y; Nakagawa K; Tamura T; Kubota K; Yamamoto N; Adachi S; Nambu Y; Fujimoto T; Nishiwaki Y; Saijo N; Fukuoka M
Clin Cancer Res; 2008 Jul; 14(13):4206-12. PubMed ID: 18594001
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
Reid T; Valone F; Lipera W; Irwin D; Paroly W; Natale R; Sreedharan S; Keer H; Lum B; Scappaticci F; Bhatnagar A
Lung Cancer; 2004 Sep; 45(3):381-6. PubMed ID: 15301879
[TBL] [Abstract][Full Text] [Related]
16. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
Altorki N; Lane ME; Bauer T; Lee PC; Guarino MJ; Pass H; Felip E; Peylan-Ramu N; Gurpide A; Grannis FW; Mitchell JD; Tachdjian S; Swann RS; Huff A; Roychowdhury DF; Reeves A; Ottesen LH; Yankelevitz DF
J Clin Oncol; 2010 Jul; 28(19):3131-7. PubMed ID: 20516450
[TBL] [Abstract][Full Text] [Related]
17. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
[TBL] [Abstract][Full Text] [Related]
18. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
20. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
Leithner K; Stacher E; Wurm R; Ploner F; Quehenberger F; Wohlkoenig C; Bálint Z; Polachova J; Olschewski A; Samonigg H; Popper HH; Olschewski H
Lung Cancer; 2009 Jul; 65(1):98-104. PubMed ID: 19081160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]